
Cadila Healthcare Limited has informed the Exchange regarding a press release dated September 02, 2020, titled "Zydus Cadila receives final approval from the USFDA for Cisatracurium Besylate Injection".
Filed with NSE ·

Cadila Healthcare Limited has informed the Exchange regarding a press release dated September 02, 2020, titled "Zydus Cadila receives final approval from the USFDA for Cisatracurium Besylate Injection".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences